Wagner Wealth Management Corp Makes New $473,000 Investment in Becton, Dickinson and Company $BDX

Wagner Wealth Management Corp bought a new stake in Becton, Dickinson and Company (NYSE:BDX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,643 shares of the medical instruments supplier’s stock, valued at approximately $473,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. Revisor Wealth Management LLC boosted its position in Becton, Dickinson and Company by 4.6% in the third quarter. Revisor Wealth Management LLC now owns 13,066 shares of the medical instruments supplier’s stock valued at $2,339,000 after buying an additional 574 shares during the last quarter. Norway Savings Bank increased its holdings in Becton, Dickinson and Company by 9.7% in the 3rd quarter. Norway Savings Bank now owns 8,040 shares of the medical instruments supplier’s stock worth $1,439,000 after buying an additional 711 shares during the period. Net Worth Advisory Group increased its holdings in Becton, Dickinson and Company by 46.4% in the 3rd quarter. Net Worth Advisory Group now owns 5,365 shares of the medical instruments supplier’s stock worth $955,000 after buying an additional 1,701 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in Becton, Dickinson and Company by 18.9% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 43,413 shares of the medical instruments supplier’s stock worth $7,771,000 after buying an additional 6,887 shares during the last quarter. Finally, CWA Asset Management Group LLC raised its position in Becton, Dickinson and Company by 15.5% during the 3rd quarter. CWA Asset Management Group LLC now owns 3,323 shares of the medical instruments supplier’s stock worth $595,000 after buying an additional 445 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 6,906 shares of company stock valued at $1,265,855. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Trading Up 1.6%

BDX stock opened at $193.77 on Wednesday. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $195.99. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The firm has a market cap of $53.39 billion, a P/E ratio of 58.36, a PEG ratio of 12.86 and a beta of 0.21. The company’s 50-day simple moving average is $184.51 and its 200-day simple moving average is $164.26.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The business’s revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Analyst Ratings Changes

Several brokerages have commented on BDX. Piper Sandler lifted their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Barclays assumed coverage on shares of Becton, Dickinson and Company in a research note on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 price objective on the stock. Royal Bank Of Canada increased their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday, August 13th. UBS Group began coverage on shares of Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price for the company. Finally, Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and an average price target of $185.07.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.